Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal Mental Health (MAMA) Study
2024-518028-63-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postpartum depression (PPD) comparing Estradiol (Vivelle Dot) with Placebo patch (Comfeel Plus Transparent) (2 arms). Primary endpoint: Clinical postpartum depression (DSM-5). Planned start Oct 2024; status: authorised.
02
Drugs
estradiol
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on 2024-518028-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518028-63-00.